In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae

• DOI: 10.1016/j.diagmicrobio.2020.115117
• Publication Date: 2020-06-21T00:07:03Z
• Authors: Justin A. Clark; Brandon Kulengowski; David S. Burgess
• Keywords: 0301 basic medicine; Microbial Sensitivity Tests; Anti-Bacterial Agents; 3. Good health; Klebsiella pneumoniae; 03 medical and health sciences; Aminoglycosides; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Multiple, Bacterial; Sisomicin; Tobramycin; Humans; Gentamicins; Amikacin

We evaluated the in vitro activity of plazomicin against other aminoglycosides in 122 clinical carbapenem-resistant Enterobacteriaceae isolates using several clinical susceptibility breakpoints. Plazomicin had excellent in vitro activity with 98% overall susceptibility. Amikacin was the next most active with 86% overall susceptibility. This dropped to 55% when switching from Clinical Laboratory and Standards Institute to US Committee on Antimicrobial Susceptibility Testing breakpoints.